Regarding the Completion of the Share Transfer of Kyowa Pharma Chemical Co., Ltd.

TOKYO, October 1, 2026 - Kyowa Hakko Bio Co., Ltd. (President and Representative Director: Hiroshi Nagano), a consolidated subsidiary of Kirin Holdings Company, Limited (President and COO: Takeshi Minakata), hereby announces that the transfer of all shares of Kyowa Pharma Chemical Co., Ltd. (President and CEO: Hayato Miyoshi) to Dai Nippon Printing Co., Ltd. (President: Yoshinari Kitajima), as previously disclosed in the news release dated July 15, 2026, entitled "Regarding the Execution of the Share Transfer Agreement for Kyowa Pharma Chemical Co., Ltd.," was completed on October 1, 2026.

The impact of this transaction on the Kirin Group's consolidated financial results for the fiscal year ending December 31, 2026 has already been reflected in the consolidated earnings forecast announced on August 7, 2026, in connection with the financial results for the second quarter of the fiscal year ending December 31, 2026.

About Kirin Holdings

Kirin Holdings Company, Limited is a global company operating across three core business domains spanning Alcoholic Beverages, Non-alcoholic Beverages & Health Science, and Pharmaceuticals. The company traces its roots to Japan Brewery, established in 1885, which later became Kirin Brewery in 1907. Since then, Kirin has expanded its business operations by leveraging fermentation and biotechnology as core strengths. The company entered the pharmaceutical field in the 1980s, which has since grown into a global business. In 2007, the company transitioned to a pure holding company structure as Kirin Holdings, and it is now strengthening its Non-alcoholic Beverages & Health Science domain.

Under its long-term vision “Innovate2035!”, the Kirin Group is focused on creating value that encourage behavioral change among consumers and patients, creating new lifestyle habits in the areas of food and health. With a unique business portfolio spanning Alcoholic Beverages, Non-alcoholic Beverages & Health Science, and Pharmaceuticals, the Group will further expand group-wide initiatives that support both mental and physical well-being.

The Kirin Group will continue to advance innovation through the combined strength of its people and technology, creating both social and economic value as a global leader in CSV*, while pursuing sustainable, long-term growth in corporate value.

*Creating Shared Value: combined added value for consumers as well as for society at large.